Varlitinib
- Generic Name
- Varlitinib
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19ClN6O2S
- CAS Number
- 845272-21-1
- Unique Ingredient Identifier
- 846Y8197W1
- Background
Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 22
- Registration Number
- NCT03499626
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
Open, Single-dose/-Period Study to Assess Mass Balance Recovery, Metabolite Profile/Identification of 14C-Varlitinib
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT03368846
- Locations
- 🇬🇧
Quotient Clinical Ltd, Nottingham, United Kingdom
Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT03231176
- Locations
- 🇨🇳
No.81 Hospital of The Chinese People's Liberation Army, Nanjing, China
🇨🇳There is 22 sites located in other cities of China, including Nanjing, Nanjing, China
Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT03130790
- Locations
- 🇰🇷
11 Sites, Seoul, Korea, Republic of
🇹🇭1 Site, Pathum Thani, Thailand
🇲🇾2 Sites, Kuala Lumpur, Malaysia
Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer
- Conditions
- Advanced or Metastatic Biliary Tract Cancer
- Interventions
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- ASLAN Pharmaceuticals
- Registration Number
- NCT03129074
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
- Conditions
- Biliary Tract Cancer
- Interventions
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 151
- Registration Number
- NCT03093870
- Locations
- 🇺🇸
Karmanos Cancer Institute/Wayne State University, Detroit, Michigan, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇯🇵There are 7 sites in different cities in Japan, Chiba, Japan
A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours
- Conditions
- Advanced or Metastatic Biliary Tract CancerAdvanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT03082053
- Locations
- 🇯🇵
ASLAN Selected sites, Tokyo, Japan
Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC
- Conditions
- Biliary Tract Cancer
- Interventions
- First Posted Date
- 2016-12-14
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 204
- Registration Number
- NCT02992340
Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT02648425
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Taipei Veterans General Hospital, Taipei, Taiwan
🇭🇰Queen Mary Hospital, Hong Kong, Hong Kong
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2018-05-29
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT02609958
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.